E

Euroapi SAS
PAR:EAPI

Watchlist Manager
Euroapi SAS
PAR:EAPI
Watchlist
Price: 2.744 EUR -0.8% Market Closed
Market Cap: 262.3m EUR

Wall Street
Price Targets

EAPI Price Targets Summary
Euroapi SAS

Wall Street analysts forecast EAPI stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EAPI is 2.856 EUR with a low forecast of 2.525 EUR and a high forecast of 3.15 EUR.

Lowest
Price Target
2.525 EUR
8% Downside
Average
Price Target
2.856 EUR
4% Upside
Highest
Price Target
3.15 EUR
15% Upside
Euroapi SAS Competitors:
Price Targets
002821
Asymchem Laboratories Tianjin Co Ltd
12% Upside
GLENMARK
Glenmark Pharmaceuticals Ltd
24% Upside
VETO
Vetoquinol SA
29% Upside
13
HUTCHMED (China) Ltd
64% Upside
MVP
Medical Developments International Ltd
27% Upside
AUROPHARMA
Aurobindo Pharma Ltd
22% Upside
REC
Recordati Industria Chimica e Farmaceutica SpA
12% Upside

Revenue
Forecast

Revenue Estimate
Euroapi SAS

For the last 4 years the compound annual growth rate for Euroapi SAS's revenue is -1%. The projected CAGR for the next 3 years is 0%.

-1%
Past Growth
0%
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Euroapi SAS

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-67%
Average Miss

Net Income
Forecast

Net Income Estimate
Euroapi SAS

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is EAPI's stock price target?
Price Target
2.856 EUR

According to Wall Street analysts, the average 1-year price target for EAPI is 2.856 EUR with a low forecast of 2.525 EUR and a high forecast of 3.15 EUR.

What is Euroapi SAS's Revenue forecast?
Projected CAGR
0%

For the last 4 years the compound annual growth rate for Euroapi SAS's revenue is -1%. The projected CAGR for the next 3 years is 0%.

Back to Top